Literature DB >> 24746577

MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer.

Hanne D Heerkens1, Marco van Vulpen2, Cornelis A T van den Berg2, Rob H N Tijssen2, Sjoerd P M Crijns2, Izaak Q Molenaar3, Hjalmar C van Santvoort3, Onne Reerink2, Gert J Meijer2.   

Abstract

BACKGROUND AND
PURPOSE: To characterize pancreatic tumor motion and to develop a gating scheme for radiotherapy in pancreatic cancer.
MATERIALS AND METHODS: Two cine MRIs of 60s each were performed in fifteen pancreatic cancer patients, one in sagittal direction and one in coronal direction. A Minimum Output Sum of Squared Error (MOSSE) adaptive correlation filter was used to quantify tumor motion in craniocaudal, lateral and anteroposterior directions. To develop a gating scheme, stability of the breathing phases was examined and a gating window assessment was created, incorporating tumor motion, treatment time and motion margins.
RESULTS: The largest tumor motion was found in craniocaudal direction, with an average peak-to-peak amplitude of 15mm (range 6-34mm). Amplitude of the tumor in the anteroposterior direction was on average 5mm (range 1-13mm). The least motion was seen in lateral direction (average 3mm, range 2-5mm). The end exhale position was the most stable position in the breathing cycle and tumors spent more time closer to the end exhale position than to the end inhale position. On average, a margin of 25% of the maximum craniocaudal breathing amplitude was needed to achieve full target coverage with a duty cycle of 50%. When reducing the duty cycle to 50%, a margin of 5mm was sufficient to cover the target in 11 out of 15 patients.
CONCLUSION: Gated delivery for radiotherapy of pancreatic cancer is best performed around the end exhale position as this is the most stable position in the breathing cycle. Considerable margin reduction can be established at moderate duty cycles, yielding acceptable treatment efficiency. However, motion patterns and amplitude do substantially differ between individual patients. Therefore, individual treatment strategies should be considered for radiotherapy in pancreatic cancer.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gating; MRI; Magnetic resonance imaging; Motion; Pancreatic cancer; Radiotherapy

Mesh:

Year:  2014        PMID: 24746577     DOI: 10.1016/j.radonc.2014.03.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

1.  Performance of a clinical gridded electron gun in magnetic fields: Implications for MRI-linac therapy.

Authors:  Brendan Whelan; Lois Holloway; Dragos Constantin; Brad Oborn; Magdalena Bazalova-Carter; Rebecca Fahrig; Paul Keall
Journal:  Med Phys       Date:  2016-11       Impact factor: 4.071

2.  Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: A review from NRG oncology.

Authors:  Edward D Brandner; Indrin J Chetty; Tawfik G Giaddui; Ying Xiao; M Saiful Huq
Journal:  Med Phys       Date:  2017-04-20       Impact factor: 4.071

3.  Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy.

Authors:  Guangyin Wu; Vivek Verma; Matthias F Haefner; Sicong Li; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2017-08

4.  Adaptive motion mapping in pancreatic SBRT patients using Fourier transforms.

Authors:  Bernard L Jones; Tracey Schefter; Moyed Miften
Journal:  Radiother Oncol       Date:  2015-04-15       Impact factor: 6.280

5.  Development of a hybrid magnetic resonance/computed tomography-compatible phantom for magnetic resonance guided radiotherapy.

Authors:  Min-Joo Kim; Seu-Ran Lee; Kyu-Ho Song; Hyeon-Man Baek; Bo-Young Choe; Tae Suk Suh
Journal:  J Radiat Res       Date:  2020-03-23       Impact factor: 2.724

Review 6.  Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Cédric Panje; Nikolaus Andratschke; Thomas B Brunner; Maximilian Niyazi; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2016-10-24       Impact factor: 3.621

7.  Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Authors:  Jordan Kharofa; Susan Tsai; Tracy Kelly; Clint Wood; Ben George; Paul Ritch; Lauren Wiebe; Kathleen Christians; Douglas B Evans; Beth Erickson
Journal:  Radiother Oncol       Date:  2014-10-15       Impact factor: 6.280

8.  Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT.

Authors:  Yijun Ding; Warren G Campbell; Moyed Miften; Yevgeniy Vinogradskiy; Karyn A Goodman; Tracey Schefter; Bernard L Jones
Journal:  Pract Radiat Oncol       Date:  2019-04-02

9.  An evaluation of motion mitigation techniques for pancreatic SBRT.

Authors:  Warren G Campbell; Bernard L Jones; Tracey Schefter; Karyn A Goodman; Moyed Miften
Journal:  Radiother Oncol       Date:  2017-05-29       Impact factor: 6.280

10.  A fast volumetric 4D-MRI with sub-second frame rate for abdominal motion monitoring and characterization in MRI-guided radiotherapy.

Authors:  Jing Yuan; Oi Lei Wong; Yihang Zhou; Kin Yin Chueng; Siu Ki Yu
Journal:  Quant Imaging Med Surg       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.